A phase II study on Mefatinib as first‐line treatment of patients with advanced non‐small‐cell lung cancer harboring uncommon <i>EGFR</i> mutations-Reference-Cited by-同舟云学术

A phase II study on Mefatinib as first‐line treatment of patients with advanced non‐small‐cell lung cancer harboring uncommon EGFR mutations

Published:2023-06-15 Issue:9 Volume:43 Page:1059-1063
ISSN:2523-3548
Container-title:Cancer Communications
language:en
Short-container-title:Cancer Communications

Author:

Wang Pingli¹^ORCID,Cao Liming²,Tian Panwen³,Ren Shengxiang⁴,Miao Liyun⁵,Zhou Chengzhi⁶,Fan Yun⁷,Li Yuping⁸,Lv Dongqing⁹,Zhao Xin¹⁰,Yang Mei¹¹,Zhu Chaonan¹¹,Yu Bing¹¹,Xu June¹¹,Song Yong¹²,Wang Kai¹¹³^ORCID

Affiliation:

1. Department of Respiratory and Critical Care Medicine The Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou Zhejiang P. R. China

2. Department of Respiratory Medicine Xiangya Hospital Central South University Changsha Hunan P. R. China

3. Department of Respiratory and Critical Care Medicine West China Hospital of Sichuan University Chengdu Sichuan P. R. China

4. Department of Medical Oncology Shanghai Pulmonary Hospital Shanghai P. R. China

5. Department of Respiratory Medicine The Affiliated Drum Tower Hospital of Nanjing University Medical School Nanjing Jiangsu P. R. China

6. Department of Pulmonary and Critical Care Medicine The First Affiliated Hospital of Guangzhou Medical University Guangzhou Guangdong P. R. China

7. Department of Medical Thoracic Oncology Cancer Hospital of University of Chinese Academy of Sciences Hangzhou Zhejiang P. R. China

8. Department of Pulmonary and Critical Care Medicine The First Affiliated Hospital of Wenzhou Medical University Wenzhou Zhejiang P. R. China

9. Department of Respiratory Medicine Taizhou Hospital of Zhejiang Province Taizhou Zhejiang P. R. China

10. Department of Respiratory and Critical Care Medicine Jiangsu Province Hospital The First Affiliated Hospital of Nanjing Medical University Nanjing Jiangsu P. R. China

11. Huadong Global Development Center Hangzhou ZhongMei HuaDong Pharmaceutical Company Hangzhou Zhejiang P. R. China

12. Department of Respiratory Medicine General Hospital of Eastern Theater Command Nanjing Jiangsu P. R. China

13. Department of Respiratory and Critical Care Medicine The Fourth Affiliated Hospital of Zhejiang University School of Medicine Yiwu Zhejiang P. R. China

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cac2.12456

Reference10 articles.

1. Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung Cancer

2. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6

3. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations

4. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

5. Osimertinib for Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)